These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 24314738

  • 1. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V, Flamand V, Crouzet S, Ploussard G.
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [Abstract] [Full Text] [Related]

  • 2. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T, Azad A, Stewart C, Gao J, Eigl BJ, Gleave ME, Joshua AM, Black PC, Chi KN.
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [Abstract] [Full Text] [Related]

  • 6. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS, Hong SJ.
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [Abstract] [Full Text] [Related]

  • 9. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use.
    Gravanis I, Lopez AS, Hemmings RJ, Jiménez JC, Garcia-Carbonero R, Gallego IG, Giménez EV, O'Connor D, Giuliani R, Salmonson T, Pignatti F.
    Oncologist; 2013 Mar; 18(9):1032-42. PubMed ID: 23966222
    [Abstract] [Full Text] [Related]

  • 10. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
    Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ.
    Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 12. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A, Pasquier D, Massard C, Berdah JF, Culine S, Penel N.
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [Abstract] [Full Text] [Related]

  • 13. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ, Abiraterone Global EAP Investigators.
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [Abstract] [Full Text] [Related]

  • 14. Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
    Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G.
    Oncotarget; 2016 Jun 28; 7(26):40085-40094. PubMed ID: 27223078
    [Abstract] [Full Text] [Related]

  • 15. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S.
    Eur Urol; 2016 May 28; 69(5):924-32. PubMed ID: 26508309
    [Abstract] [Full Text] [Related]

  • 16. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov 28; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 17. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul 28; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 18. [Castration resistant prostate cancer 2011].
    Miller K.
    Aktuelle Urol; 2011 Mar 28; 42(2):95-102. PubMed ID: 21437832
    [Abstract] [Full Text] [Related]

  • 19. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
    Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS.
    J Clin Oncol; 2010 Mar 20; 28(9):1489-95. PubMed ID: 20159823
    [Abstract] [Full Text] [Related]

  • 20. [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].
    Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
    Urologe A; 2016 Sep 20; 55(9):1206-12. PubMed ID: 27411995
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.